Clinical trial: randomized, double‐blind, placebo‐controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4
Clinical trial: randomized, double‐blind, placebo‐controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4
复制标题
临床试验：硝唑尼特单药治疗基因 4 型慢性丙型肝炎患者的随机、双盲、安慰剂对照研究
DOI：
10.1111/j.1365-2036.2008.03781.x
复制
发表时间：
2008
影响因子：
7.6
通讯作者：
E. Keeffe
中科院分区：
文献类型：
--
作者：
Jean–François Rossignol;S. Kabil;Y. el;A. Elfert;E. Keeffe
背景：硝唑尼特在美国被批准用于治疗隐孢子虫和贾第鞭毛虫，它能抑制复制子系统中的丙型肝炎病毒复制。
Background Nitazoxanide, licensed in the US for treatment of Cryptosporidium parvum and Giardia lamblia, inhibits hepatitis C virus replication in replicon systems.